Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This phase I single center open labeled study is planned to assess the safety and
tolerability of bevacizumab for treating patients with bilateral Recurrent Respiratory
Papillomatosis (RRP). Approximately 20 patients will receive bevacizumab directly injected
into the vocal folds. Patients who enroll in the protocol will be injected with bevacizumab
in one vocal fold that represents the more diseased of the two folds. A sham injection with
saline will be administered to the other vocal fold as the control. This therapy will be
administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the
initial treatment always getting the drug injection. The investigator will also treat lesions
by laser photoangiolysis of both vocal folds using the 532 nm potassium-titanyl-phosphate
(KTP) laser.